FUNDAMENTALS · Fundamentals · KR Healthcare

Dentium (145720) Fundamentals 2026 — P/E 15.1x, Revenue Analysis | SniperIQ

Dentium (145720) is a KR-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ₩322.5B, trading at ₩37400.00 on the KSC. This SniperIQ fundamentals page covers Dentium's valuation (P/E 15.1x, P/B 0.5x), profitability (net margin 6.3%), revenue (₩346.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩322.5B
P/E (TTM)15.1x
Net Margin6.3%
Revenue (FY25)₩346.5B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Dentium's market cap?

Dentium (145720) has a market capitalization of approximately ₩322.5B, trading at ₩37400.00 on the KSC. Market cap moves with the live share price.

What is Dentium's P/E ratio?

Dentium's trailing twelve-month P/E ratio is 15.1x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Dentium?

Dentium runs a net profit margin of 6.3%, a gross margin of 63.0%, and an operating margin of 20.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Dentium generate?

Dentium reported revenue of ₩346.5B for fiscal year 2025, with net income of ₩16.8B and earnings per share (EPS) of 1948.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Dentium pay a dividend?

Dentium offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Dentium financially healthy?

Dentium carries a debt-to-equity ratio of 0.53x and a current ratio of 1.50x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Dentium a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dentium (145720) the key facts are: market cap ₩322.5B, P/E 15.1x, revenue ₩346.5B, 52-week range 37250-68800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Dentium's full fundamentals live

Get Dentium's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Curexo (060280) fundamentals · PT Diagnos Laboratorium Utama (DGNS) fundamentals · PT Royal Prima (PRIM) fundamentals · Merck & (MRK) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons